Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
সব দামের পরিবর্তন →ইঙ্গিত ও ব্যবহার
Avifix contains Nelfinavir and is used to treat HIV infection in patients for whom antiretroviral therapy is appropriate.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
For adults, the recommended dose is 1250 mg (five 250 mg tablets) twice daily, or alternatively 750 mg (three 250 mg tablets) three times daily. Nelfinavir should be taken with a meal. Its antiviral activity is enhanced when it is given together with nucleoside analogues, so it is recommended that Nelfinavir be used in combination with nucleoside analogues. For paediatric patients aged 2 to 13 years, the recommended oral dose of Nelfinavir is 20 to 30 mg/kg per dose, given three times daily with a meal.
পার্শ্বপ্রতিক্রিয়া
The safety of Avifix was studied in over 1500 patients who received drug either alone or in combination with nucleoside analogues. The majority of adverse events were of mild intensity. The most frequently reported adverse event among patients receiving Avifix was diarrhoea, which was generally of mild to moderate intensity. Adverse events occurring in less than 2% of patients receiving Avifix in all phase II/III clinical trials and considered at least possibly related or of unknown relationship to treatment and of at least moderate severity are listed below.General: Abdominal pain, accidental injury, allergic reaction, asthenia, back pain, fever, headache, malaise, pain and redistribution/accumulation of body fat.Digestive system: Anorexia, dyspepsia, epigastric pain, gastrointestinal bleeding, hepatitis, mouth ulceration, pancreatitis and vomiting.Haemic/Lymphatic system: Anaemia, leukopenia and thrombocytopenia.Metabolic/Nutritional: Increase in alkaline phosphate, amylase, creatinine phosphokinase, lactic dehydrogenase, SGOT, SGPT and g glutamyl transpeptidase, hyperlipaemia, hyperuricaemia, hyperglycaemia, hypoglycaemia, dehydration and liver function tests abnormal.Musculoskeletal system: Arthralgia, arthritis, cramps, myalgia, myasthenia and myopathy.Nervous system: Anxiety, depression, dizziness, emotional lability, hyperkinesia, insomnia, migraine, paraesthesia, seizures, sleep disorder, somnolence and suicide ideation.Respiratory system: Dyspnoea, pharyngitis, rhinitis and sinusitis.Skin/Appendages: Dermatitis, folliculitis, fungal dermatitis, maculopapular rash, pruitus, sweating, and urticaria.Ophthalmic: Acute iritis and eye disorder.Urogenital system: Kidney calculas, sexual dysfunction.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Avifix should not be administered concurrently with Terfenadine, Astemizole, Cisapride, Triazolam, Midazolam, Ergot derivatives, Amiodarone or Quinidine because Avifix may affect the hepatic metabolism of these drugs and create potential for serious and/or life-threatening adverse events. New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus and hyperglycaemia have been reported during post-marketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycaemic agents for treatment of these events. In some cases diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycaemia persisted in some cases. General: Avifix is principally metabolised by the liver. Therefore, caution should be exercised when administering Avifix to patients with hepatic impairment.Haemophilia: There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis, in patients with haemophilia type A and B treated with protease inhibitors. In some patients, additional factor VIII was given. In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced. A causal relationship has not been established.
নিষেধাজ্ঞা
Nelfinavir must not be used in patients known to have a clinically significant hypersensitivity to it or to any of its components. Avifix must not be given together with drugs that rely heavily on the CYP3A enzyme for clearance, when raised plasma levels of those drugs could lead to serious or life-threatening adverse events.